Abatacept in Treating Adults With Mild Relapsing Wegener’s Granulomatosis

Related Clinical Trial
Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia. Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator PR3-AAV Resilient Remission or PRRR Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Hydroxychloroquine in ANCA Vasculitis Evaluation Vasculitis Illness Perception (VIP) Study Reproductive Health in Men and Women With Vasculitis Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Impact of Vasculitis on Employment and Income Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases VCRC Tissue Repository Yellow Fever Vaccine in Patients With Rheumatic Diseases Journey of Patients With Vasculitis From First Symptom to Diagnosis One-Time DNA Study for Vasculitis Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Clinical Transcriptomics in Systemic Vasculitis (CUTIS) The ANCA Vasculitis Questionnaire (AAV-PRO©) Vasculitis Pregnancy Registry VCRC Patient Contact Registry Patient-Reported Data Validation Study Educational Needs of Patients With Systemic Vasculitis Diagnostic Effectiveness of Virtual Bronchoscopy Alemtuzumab for ANCA Associated Refractory Vasculitis Interventional Cryotherapy for the Eradication of Benign Airway Disease (“ICE the BAD”) PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Plasma Exchange for Renal Vasculitis PRO Development for ANCA Associated Vasculitis BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Rituximab Vasculitis Maintenance Study Anti-Cytokine Therapy for Vasculitis Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Low-dose Glucocorticoid Vasculitis Induction Study Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. The Assessment of Prednisone In Remission Trial (TAPIR) – Patient Centric Approach Steroids and Methotrexate to Treat Systemic Vasculitis Efficacy Study of Two Treatments in the Remission of Vasculitis Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography The Assessment of Prednisone In Remission Trial – Centers of Excellence Approach Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s) Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener’s) and Microscopic Polyangiitis Mycophenolate Mofetil for Treatment of Relapses of Wegener’s Disease or Microscopic Polyangiitis (MPA) Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Daclizumab to Treat Wegener’s Granulomatosis An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener’s Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Etanercept to Treat Wegener’s Granulomatosis Treatment of Wegener’s Granulomatosis With Cyclophosphamide Mycophenolate Mofetil to Treat Wegener’s Granulomatosis and Related Vascular Inflammatory Conditions Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener’s Granulomatosis Comparison of Treatments to Maintain Disease Remission in Patients With Wegener’s Granulomatosis and Related Vasculitis Syndromes Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener’s Granulomatosis) Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study Analysis of Bronchial Tissue and Fluid in Patients With Wegener’s Granulomatosis TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Study of One Protein Implicated in Wegener Disease Abatacept in Treating Adults With Mild Relapsing Wegener’s Granulomatosis Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis Etanercept for Wegener’s Granulomatosis Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis

Brief Title

Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis

Official Title

A Multi-Center, Open-label Pilot Study of Abatacept (CTLA4-Ig) in the Treatment of Mild Relapsing Wegener's Granulomatosis

Brief Summary

      Wegener's granulomatosis (WG) is a rare disease that causes inflammation of blood vessels, or
      vasculitis. It may involve many different parts of the body, but typically affects the upper
      and lower respiratory tract and kidneys. The purpose of this study is to determine the safety
      and effectiveness of the medication abatacept in treating adults with mild relapsing WG.

Detailed Description

      Current standard treatment for WG involves various medications and is based on disease
      severity. Unfortunately, more than 50% of people experience a relapse after remission,
      placing them at risk for additional organ damage and medication toxicity. To prevent this,
      safer and more effective treatments for mild relapses are needed. Several studies have shown
      that activated T cells, a type of white blood cell important in regulating immune responses,
      play a role in WG. Abatacept, an immunoglobulin-based medication approved by the FDA to treat
      rheumatoid arthritis, acts by preventing T-cell activation and may be useful in treating mild
      relapses of WG. The purpose of this study is to determine the safety and effectiveness of
      abatacept in treating adults with mild relapsing WG.

      Participants will receive abatacept intravenously at study visits on Days 1, 15, and 29, and
      then once a month thereafter. A participant's abatacept dose is based on body weight and will
      remain the same throughout the study. Participants who are receiving maintenance
      immunosuppressive medications consisting of methotrexate, azathioprine, or mycophenolate
      mofetil at the time of enrollment will remain on these medications without dosage increase or
      reduction. Eligible participants may be on up to prednisone 15mg daily at the time of
      relapse. Following the development of relapse, participants may be treated with up to
      prednisone 30mg daily if necessary, but must to be back to the same dose that they had been
      on prior to relapse by Month 2. All study visits include medication review, physical exam,
      blood and urine collection, and questionnaires. A chest x-ray, computed tomography (CT) scan
      of the chest and sinuses, and lung function testing will occur at some study visits.
      Participants whose symptoms did not improved by Month 2 will be taken off abatacept. Any
      participants undergoing early termination or, after common closing, will undergo three
      follow-up study visits at 1, 3, and 6 months after the end of treatment.

Study Phase

Phase 1/Phase 2

Study Type


Primary Outcome

Safety of Abatacept - Number of Participants With Adverse Events

Secondary Outcome

 Disease Remission


Wegener's Granulomatosis



Study Arms / Comparison Groups

Description:  Participants will receive abatacept intravenously at study visits on Days 1, 15, and 29, and then once a month thereafter.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

February 2008

Completion Date

August 2011

Primary Completion Date

August 2011

Eligibility Criteria

        Inclusion Criteria:

          -  Diagnosis of WG, meeting at least 2 of the 5 modified American College of Rheumatology
             (ACR) criteria. More information about this criterion can be found in the protocol.

          -  Relapse of WG within the past 28 days where disease activity is confined to one or
             more of the following sites and where the symptoms/signs are of such a nature that the
             usual treatment would consist of the reinstitution or increase in GC to no more than
             prednisone 30mg daily and/or an increase or addition of a second immunosuppressive
             agent other than CYC (more specific information about this criterion can be found in
             the protocol):

               1. Sinonasal disease

               2. Oral mucosa ulceration

               3. Skin disease

               4. Musculoskeletal disease

               5. Pulmonary parenchymal disease

               6. Mild ocular disease

               7. Subglottic inflammation without significant stenosis

               8. Otic disease

               9. Breast involvement

              10. Urogenital involvement

              11. Other mild disease

          -  Age of 15 years or older

          -  Willing and able to undergo treatment and attend follow-up visits

          -  Willing to use effective forms of contraception throughout the study

        Exclusion Criteria:

          -  Disease involvement that does not meet the criteria for mild disease. More information
             about this criterion can be found in the protocol.

          -  Disease activity that would usually be treated first with cyclophosphamide

          -  Presence of disease activity for which the investigator would normally treat the
             participant with more than prednisone 30 mg daily.

          -  Receiving cyclophosphamide at study entry

          -  Treatment with prednisone at a dose of more than 15 mg daily at the time of relapse.
             Subjects will be eligible if prednisone was initiated or dose increased in the period
             between relapse and study enrollment provided that the prednisone dose was 15 mg daily
             or less at the time when the relapse occurred, the prednisone dosage was increased no
             higher than 30 mg daily following the recognition of relapse, and that the dosage
             increase was made no more than 28 days prior to enrollment.

          -  Active infection

          -  HIV infected, hepatitis C virus infected, or positive for hepatitis B

          -  Unable to follow through with study participation

          -  Cytopenia, defined as platelet count less than 80,000/mm3, absolute neutrophil count
             less than 1500/mm3, OR hematocrit less than 20%

          -  Kidney insufficiency

          -  Use of illegal drugs

          -  Any other uncontrolled disease that would prevent participation

          -  History of cancer. More information about this criterion can be found in the protocol.

          -  Received an investigational medication or procedure within 30 days of study entry

          -  Received a live vaccine within 4 weeks of study entry

          -  Positive tuberculin skin test. More information about this criterion can be found in
             the protocol.

          -  Tuberculosis as indicated by radiographic evidence

          -  Past treatment with rituximab within the past 12 months, or past treatment with
             rituximab more than 12 months ago where the B lymphocyte count has not returned to

          -  Certain other diseases. More information about this criterion can be found in the

          -  Pregnant or breastfeeding




15 Years - N/A

Accepts Healthy Volunteers



Carol A. Langford, MD, MHS, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID

RDCRN 5522

Secondary IDs


Responsible Party


Study Sponsor

University of Pennsylvania


 Office of Rare Diseases (ORD)

Study Sponsor

Carol A. Langford, MD, MHS, Principal Investigator, The Cleveland Clinic

Verification Date

December 2015